Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$34.40
-2.2%
$34.09
$26.47
$41.61
$2.02B0.84569,685 shs726,870 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$24.27
-0.3%
$22.07
$13.45
$41.08
$2.13B0.09982,643 shs860,814 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.02
-0.5%
$6.17
$5.41
$21.57
$523.78M0.411.24 million shs1.19 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$33.68
+0.3%
$34.67
$27.12
$55.33
$2.01B2.37891,336 shs1.38 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-2.22%-8.32%+7.13%+13.46%+1.59%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-0.33%-0.94%+10.72%+15.96%-43.62%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-0.50%-3.37%+3.61%-6.96%-71.07%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+0.33%-6.42%-10.62%-14.17%-39.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.7824 of 5 stars
4.51.00.00.04.23.34.4
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.0764 of 5 stars
4.41.00.04.42.51.70.0
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3.3434 of 5 stars
3.41.00.04.70.60.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.5578 of 5 stars
3.40.00.04.43.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.00
Buy$51.0048.26% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.77
Moderate Buy$48.0998.15% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50306.98% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4049.64% Upside

Current Analyst Ratings Breakdown

Latest KURA, TWST, HRMY, and IDYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$66.00 ➝ $72.00
7/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
7/21/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$48.00
7/10/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $55.00
7/10/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$33.00
7/10/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$25.00
7/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$714.73M2.76$2.88 per share11.94$11.56 per share2.98
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M303.65N/AN/A$12.25 per share1.98
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M9.67N/AN/A$5.32 per share1.13
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.45N/AN/A$8.07 per share4.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$145.49M$2.6213.1311.060.4820.53%24.32%15.92%8/5/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/7/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest KURA, TWST, HRMY, and IDYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$0.15N/AN/AN/A$64.95 millionN/A
8/5/2025Q2 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.78N/AN/AN/A$204.37 millionN/A
8/5/2025Q2 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.85N/AN/AN/A$3.48 millionN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.22
3.67
3.63
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
23.60%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.50%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million43.87 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Preview: Twist Bioscience's Earnings
Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$34.40 -0.78 (-2.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$34.38 -0.02 (-0.04%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$24.27 -0.08 (-0.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$24.28 +0.01 (+0.04%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.02 -0.03 (-0.50%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$6.02 0.00 (-0.08%)
As of 08/1/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.68 +0.11 (+0.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$33.98 +0.30 (+0.89%)
As of 08/1/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.